Toggle Offcanvas
...
 
Ustekinumab Tenders

Ustekinumab Tenders

View Ustekinumab tenders, RFPs and contracts. Bid on readily available Ustekinumab tenders with the best and most comprehensive tendering platform, since 2002.

Bidding for Ustekinumab tenders is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Ustekinumab.

Global Tenders stands out as the largest platform dedicated to pharmaceutical tenders and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Tenders/RFPs/Contracts Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to tender information, we offer in-depth Ustekinumab market analysis, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Ustekinumab tenders, advanced search filters, market analysis, industry trends, tender training and 24/7 customer support.

37 Live Notices for Ustekinumab Tenders

Showing 1 to 20

Department Of Defense Pharamacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
country United States
posting date30 May 2025
deadline20 Jun 2025
Medicinal Products With The Active Substance Of The Ustekinumab
country Czech Republic
posting date23 May 2025
deadline23 Jun 2025
Completion Of Non-Exclusive Discount Agreements According To Section 130A (8) Sgb V (Open House Model)
country Germany
posting date20 May 2025
deadline01 May 2027
Completion Not Excl. Pharmaceutical Discount Club. According To Section 130A (8) Sgb V By Means Of An Open House Model To The Active Ingredient Ustekinumab (Atc Code According To Who: L04Ac05)
country Germany
posting date19 May 2025
deadline31 Jul 2026
Completion Not Excl. Pharmaceutical Discount Club. According To Section 130A (8) Sgb V By Means Of An Open House Model To The Active Ingredient Ustekinumab (Atc Code According To Who: L04Ac05)
country Germany
posting date19 May 2025
deadline31 Jul 2026
Supply Of Unsumab (Doe) And Rilpirivina (Doe)
country Spain
posting date19 May 2025
deadline03 Jun 2025
Supply Of Ustekinumab To The Pharmacy Services Of The Centers Dependent On The Navarro Health -Osunbidea Service (F111 - 2025).
country Spain
posting date15 May 2025
deadline12 Jun 2025
Supply Of Ustekinumab To The Pharmacy Services Of The Centers Dependent On The Navarro Health -Osunbidea Service (F111 - 2025).
country Spain
posting date14 May 2025
deadline12 Jun 2025
F111-2025 Framework Agreement Relating To The Supply Of Unsumab To The Pharmacy Services Of The Centers Dependent On The Navarro Health-Osasunbidea Service.
country Spain
posting date13 May 2025
deadline12 Jun 2025
Supply Of Unsumab For Pharmacy Services Of The Miguel Servet University Hospital And General Hospital Of The Defense Of Zaragoza
country Spain
posting date13 May 2025
deadline09 Jun 2025
Supply Of Unsumab For Pharmacy Services Of The Miguel Servet University Hospital And General Hospital Of The Defense Of Zaragoza
country Spain
posting date13 May 2025
deadline09 Jun 2025
Supply Of Unsumab For Pharmacy Services Of The Miguel Servet University Hospital And General Hospital Of The Defense Of Zaragoza
country Spain
posting date12 May 2025
deadline09 Jun 2025
Pharmaceutical Discount Agreements Pursuant To Section 130A Paragraph 8 Of The Social Security Code (Sgb V) Within The Framework Of Open-House Procedures
country Germany
posting date31 Jan 2025
deadline06 May 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Security Code (Sgb) V For The Active Ingredient Ustekinumab, (Obg) Atc L04Ac05 For The Period 01.03.2025 - 28.02.2027
country Germany
posting date16 Jan 2025
deadline05 Jan 2027
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Security Code (Sgb) V For The Active Ingredient Ustekinumab, (Obg) Atc L04Ac05 For The Period 01.03.2025 - 28.02.2027
country Germany
posting date16 Jan 2025
deadline05 Jan 2027
Environmentally Friendly Supply Of Biological Human Medicines With Biosimilars For Public Health Centres In Valencia
country Spain
posting date30 Dec 2024
deadline01 Oct 2025
Pharmaceutical Discount Agreements From February 1, 2025 For Various Active Ingredients Within The Framework Of An Open-House Procedure
country Germany
posting date12 Dec 2024
deadline02 Dec 2026
Conclusion Of Non-Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8 Of The Social Security Code (Sgb) V For Medicinal Products (Open House Procedure)
country Germany
posting date30 Oct 2024
deadline20 Apr 2026
Medicines Containing The Active Substance Ustekinumab (Atc: L04Ac05)
country Germany
posting date22 Jun 2024
deadline31 May 2026
Conclusion Of A Non-Exclusive Discount Agreement According To Section 130A Paragraph 8 Sgb V For The Active Ingredient Ustekinumab, Atc L04Ac05 (Obo) For The Period 01.08.2024 - 31.07.2025 (Plus Extension Option 1X12 Months)
country Germany
posting date22 Jun 2024
deadline05 Jun 2026

Share Share this page